Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
rated new Overweight at Morgan Stanley. $26 price target. Company is operating in an attractive and underpenetrated region.
downgraded at Stifel from Hold to Sell. Stock is already pricing in a potential takeover.
upgraded at Credit Suisse to Neutral from Underperform as management's comments eased concerns about competitive intensity, Credit Suisse said. Price target increased to $35 from $32.
upgraded at Wells from Market Perform to Outperform, Wells Fargo said. Company can deliver above-average production growth.
upgraded at William Blair from Market Perform to Outperform. Third-party lending fears are already priced into the stock.
East West Bancorp
downgraded at Credit Suisse to Neutral from Outperform. Margin pressure and loan runoff offset C&L loan momentum, Credit Suisse said. Price target trimmed by a dollar to $21.
downgraded at Goldman from Buy to Neutral, Goldman Sachs said. $20 price target. Sentiment should remain poor, until the ERP issue is resolved.
rated new Buy at Goldman. $57 price target. Company has a strong capital position and can improve its operating margin.
upgraded at Argus from Hold to Buy, Argus Research said. $29 price target. Company can continue to grow to become one of the largest generic drugmakers.
Research in Motion
( RIMM) downgraded at Wunderlich from Buy to Hold. $46 price target. Company is losing its foothold in the smartphone market.
rated new Hold at Capstone. $90 price target. Commodity costs are rising and the company may have limited pricing power, given its competitive industry.
( ZIP) downgraded at William Blair from Market Perform to Underperform. Consensus expectations remain too high.
( ZIP) rated new Neutral at Goldman. Valuation call, based on a $24 price target.
( ZIP) rated new Outperform at Oppenheimer. $30 price target. Company can deliver solid growth over the next several years.
End of report.
This article was written by a staff member of TheStreet.